Shuttle Pharmaceuticals Holdings, Inc. — fact timeline

Shuttle Pharmaceuticals Holdings, Inc. completed an acquisition involving United Dogecoin Inc. (closed 2026-05-06).

“On May 6, 2026 (the “ Closing Date ”), Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (“ Shuttle ” or “ Acquiror ”), completed its previously announced merger pursuant to an Agreement and Plan of Merger (the “ Merger Agreement ”), entered into on April 30, 2026 by and among the Acquiror, Shuttle Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Shuttle (“ Merger Sub ”) and United Dogecoin Inc., a Delaware corporation (the “ Company ”).”

Shuttle Pharmaceuticals Holdings, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at Securities Purchase Agreement for issuance of Series B-2 convertible preferred stock and common stoc (effective 2026-04-30).

“on April 30, 2026, the Acquiror entered into a Securities Purchase Agreement (the “ Securities Purchase Agreement ”) with certain accredited investors party thereto (each, a “ Purchaser ” and collectively, the “ Purchasers ”), pursuant to which the Acquiror agreed to issue (i) 1,910 newly designated Series B-2 convertible preferred stock, par value $0.00001 (the “ Series B-2 Preferred Stock ”) and (ii) common stock purchase warrants (the “ Common Warrants ” and together with the Series B-2 Preferred Stock, the “ PIPE Securities ”) to purchase up to 100% of the number of shares of Common Stock underlying the Series B-2 Convertible Preferred Stock as of the Closing Date, exercisable for a period of three (3) years at an exercise price of $1.03 per share (the “ PIPE Financing ”).”

Shuttle Pharmaceuticals Holdings, Inc. entered into Agreement and Plan of Merger with United Dogecoin Inc. valued at Agreement and Plan of Merger entered into on April 30, 2026 by and among Acquiror, Merger Sub and th (effective 2026-04-30).

“On May 6, 2026 (the “ Closing Date ”), Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (“ Shuttle ” or “ Acquiror ”), completed its previously announced merger pursuant to an Agreement and Plan of Merger (the “ Merger Agreement ”), entered into on April 30, 2026 by and among the Acquiror, Shuttle Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Shuttle (“ Merger Sub ”) and United Dogecoin Inc., a Delaware corporation (the “ Company ”).”

Oleh Nabyt resigned as Director at Shuttle Pharmaceuticals Holdings, Inc..

“On May 3, 2026 (the “ Termination Date ”), independent director Oleh Nabyt resigned from the Board of Directors of Shuttle, effective as of the Termination Date.”

Ryan Trasolini was appointed as Co-Chief Executive Officer at Shuttle Pharmaceuticals Holdings, Inc..

“the Board of Directors of Shuttle approved the appointment of Ryan Trasolini, Chief Executive Officer of the Company, as Co-Chief Executive Officer of the Acquiror, effective at the Effective Time.”

Shuttle Pharmaceuticals Holdings, Inc. entered into Agreement and Plan of Merger with United Dogecoin Inc. valued at Merger consideration consisting of Series B-1 convertible preferred stock and up to 118,038,551 pre- (effective 2026-04-30).

“On April 30, 2026, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (“ Shuttle ” or “ Acquiror ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Shuttle Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Shuttle (“ Merger Sub ”) and United Dogecoin Inc., a Delaware corporation (the “ Company ”).”

Shuttle Pharmaceuticals Holdings, Inc. entered into Placement Agency Agreement with E.F. Hutton & Co. valued at Placement agency agreement on a reasonable best-efforts basis, with cash fee of 4.0% of gross procee (effective 2026-03-05).

“On March 5, 2026, the Company entered into a Placement Agency Agreement (the “Placement Agency Agreement”) with E.F. Hutton & Co., as placement agent (the “Placement Agent”), pursuant to which the Placement Agent agreed to act as the Company’s exclusive placement agent in connection with the Offering.”

Shuttle Pharmaceuticals Holdings, Inc. entered into Securities Purchase Agreement with the purchasers named therein valued at The Company agreed to issue and sell 2,238,800 shares of common stock and pre-funded warrants to pur (effective 2026-03-05).

“In connection with the Offering, the Company entered into a Securities Purchase Agreement, dated March 5, 2026 (the “Purchase Agreement”), by and among the Company and the purchasers named therein, pursuant to which the Company agreed to issue and sell the shares of Common Stock and Pre-Funded Warrants.”

Shuttle Pharmaceuticals Holdings, Inc. amended First Amendment to Asset Purchase Agreement with 1563868 B.C. Ltd., 1542770 BC Ltd., ZhiTian (Andy) Zhang valued at 320,496 shares of Company Common Stock at $1.76 per share (effective 2025-12-23).

“On December 23, 2025 (the “ Effective Date ”), Shuttle Pharmaceuticals Holdings, Inc. (the “ Company ”) entered into a First Amendment (the “ Amendment ”) to Asset Purchase Agreement (the “ Agreement ”) with 1563868 B.C. Ltd., a Canadian limited corporation and the Company’s wholly owned subsidiary (“ Purchaser ”), 1542770 BC Ltd., a Canadian limited corporation (“ Seller ”), and ZhiTian (Andy) Zhang, an individual residing in Vancouver, Canada (“ Seller Guarantor ”), dated as of November 20, 2025.”

Shuttle Pharmaceuticals Holdings, Inc. completed an acquisition involving 1542770 BC Ltd. for aggregate consideration payable ... consists of: (a) a one-time cash contribution of $3,000,000, paid on the Closing Date; (ii) a first installment contribution (closed 2025-11-20).

“by or on behalf of the Purchaser for the sale, transfer, and delivery of the Transferred Assets and Transferred Liabilities consists of: (a) a one-time cash contribution of $3,000,000, paid on the Closing Date; (ii) a first installment contribution equal to $3,000,000, payable on the 6 month anniversary of the Closing Date; and (iii) a second installment”

Shuttle Pharmaceuticals Holdings, Inc. announced a restructuring affecting clinical trials of Ropidoxuridine.

“On November 20, 2025, in light of the foregoing, the Company committed to a plan to discontinue its clinical trials of Ropidoxuridine (the “Clinical Trials”), as provided for under the Master Agreement.”

Shuttle Pharmaceuticals Holdings, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“November 17, 2025 By: /s/ Christopher Cooper Christopher Cooper Interim Chief Executive Officer”

Michael P. Vander Hoek resigned as Vice President, Regulatory at Shuttle Pharmaceuticals Holdings, Inc..

“On May 9, 2025, Michael P. Vander Hoek submitted his resignation from the position of Vice President, Regulatory, of the Company, effective June 10, 2025.”

Dr. Anatoly Dritschilo resigned as Chief Scientific Offer and director at Shuttle Pharmaceuticals Holdings, Inc..

“On May 9, 2025, Dr. Anatoly Dritschilo, resigned as Chief Scientific Offer and director of Shuttle Pharmaceuticals Holdings, Inc. (the “Company”), effective immediately.”

Anatoly Dritschilo was appointed as Chief Scientific Officer at Shuttle Pharmaceuticals Holdings, Inc..

“Anatoly Dritschilo, M.D., to the position of Chief Scientific Officer. Dr. Dritschilo will also continue to hold the position of Chairman of the Board of Directors.”

Christopher Cooper was appointed as interim Chief Executive Officer at Shuttle Pharmaceuticals Holdings, Inc..

“Effective March 30, 2025, the Company’s Board of Directors approved the appointment of Christopher Cooper to the position of interim Chief Executive Officer”

Christopher Cooper was appointed as interim co-Chief Executive Officer at Shuttle Pharmaceuticals Holdings, Inc..

“On March 11, 2025, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), appointed Mr. Christopher Cooper to the position of interim co-Chief Executive Officer (“Interim Co-CEO”).”

Oleh Nabyt was appointed as Director at Shuttle Pharmaceuticals Holdings, Inc..

“the Company’s Board of Directors appointed George Scorsis, Joseph Tung, and Oleh Nabyt as directors of the Company”

Joseph Tung was appointed as Director at Shuttle Pharmaceuticals Holdings, Inc..

“the Company’s Board of Directors appointed George Scorsis, Joseph Tung, and Oleh Nabyt as directors of the Company”

George Scorsis was appointed as Director at Shuttle Pharmaceuticals Holdings, Inc..

“the Company’s Board of Directors appointed George Scorsis, Joseph Tung, and Oleh Nabyt as directors of the Company”

Joshua Shafer resigned as Director at Shuttle Pharmaceuticals Holdings, Inc..

“each of Milton Brown, Bette Jacobs, Chris Senanayake and Joshua Shafer resigned as directors of the Company”

Chris Senanayake resigned as Director at Shuttle Pharmaceuticals Holdings, Inc..

“each of Milton Brown, Bette Jacobs, Chris Senanayake and Joshua Shafer resigned as directors of the Company”

Bette Jacobs resigned as Director at Shuttle Pharmaceuticals Holdings, Inc..

“each of Milton Brown, Bette Jacobs, Chris Senanayake and Joshua Shafer resigned as directors of the Company”

Milton Brown resigned as Director at Shuttle Pharmaceuticals Holdings, Inc..

“each of Milton Brown, Bette Jacobs, Chris Senanayake and Joshua Shafer resigned as directors of the Company”

Shuttle Pharmaceuticals Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 30, 2024 the Company’s common stock had failed to maintain a minimum closing bid price of $1.00 per share, as required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2”

Michael Vander Hoek changed role as Vice President, Regulatory at Shuttle Pharmaceuticals Holdings, Inc..

“The Company’s current Chief Financial Officer, Mr. Michael Vander Hoek, who also serves as our Vice President, Regulatory, will be transitioning out of his role as Chief Financial Officer and, effective September 10, 2024, will assume the Vice President, Regulatory position on a full-time basis.”

Timothy J. Lorber was appointed as Chief Financial Officer at Shuttle Pharmaceuticals Holdings, Inc..

“On June 13, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an employment agreement (the “Employment Agreement”) with Mr. Timothy J. Lorber, CPA, 65, pursuant to which Mr. Lorber will serve as the Company’s part-time Chief Financial Officer until September 9, 2024 (the “Transition Period”) and, effective September 10, 2024, Mr. Lorber will assume the role of full-time Chief Financial Officer of the Company.”